Idera Pharmaceuticals Scientists Co-Author Paper On Preclinical Data Of Investigational Cancer Vaccine

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced the publication of a paper entitled “Treatment of Mammary Carcinomas in HER-2 Transgenic Mice through Combination of Genetic Vaccine and an Agonist of Toll-like Receptor 9″ in Clinical Cancer Research (2009, 15, 1575-84) co-authored by scientists from Idera and Merck & Co., Inc.

More: continued here

Filed under: Cancer on March 8th, 2009